

# Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2017

<https://marketpublishers.com/r/T48665BFDCFEN.html>

Date: October 2017

Pages: 66

Price: US\$ 2,000.00 (Single User License)

ID: T48665BFDCFEN

## Abstracts

Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2017

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2017, provides an overview of the Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline landscape.

Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, confusion, fever, headache, heart rate, shortness of breath, speech changes, weakness and yellowish color to the skin (jaundice). Treatment includes surgery to remove spleen and drugs that suppress the immune system, such as corticosteroids.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II and Preclinical stages are 1, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Thrombotic

Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Thrombotic Thrombocytopenic Purpura - Overview

Thrombotic Thrombocytopenic Purpura - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Thrombotic Thrombocytopenic Purpura - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Thrombotic Thrombocytopenic Purpura - Companies Involved in Therapeutics Development

Ablynx NV

Biogen Inc

Kaketsuken

Lee's Pharmaceutical Holdings Ltd

Omeros Corp

Shire Plc

Thrombotic Thrombocytopenic Purpura - Drug Profiles

caplacizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate ADAMTS13 for Thrombotic Thrombocytopenic Purpura - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-721 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant ADAMTS-13 Replacement for Thrombotic Thrombocytopenic Purpura -

Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHP-655 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZK-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Thrombotic Thrombocytopenic Purpura - Dormant Projects

Thrombotic Thrombocytopenic Purpura - Discontinued Products

Thrombotic Thrombocytopenic Purpura - Product Development Milestones

Featured News & Press Releases

Oct 16, 2017: Ablynx Establishes Subsidiary in the USA and Appoints a General Manager

Oct 02, 2017: Ablynx Announces Positive Topline Results From The Phase III Hercules Study Of Caplacizumab For The Treatment Of Acquired TTP

Jul 26, 2017: Ablynx Receives Fast Track Designation From The FDA For Caplacizumab For The Treatment Of Acquired TTP

Jun 26, 2017: Ablynx Initiates a Single And Multiple Dose Phase I Study of Caplacizumab in Healthy Japanese Subjects

May 02, 2017: Ablynx Completes Patient Recruitment in its Phase III Hercules Study of Caplacizumab for the Treatment of aTTP

Feb 06, 2017: Ablynx Submits a Marketing Authorisation Application to the European Medicines Agency for Caplacizumab, Its Anti-vWF Nanobody, for the Treatment of aTTP

Oct 10, 2016: Ablynx Initiates a Phase III Follow-Up Study of Its First-In-Class Wholly-Owned Anti-Vwf Nanobody, Caplacizumab, For the Treatment of Acquired TTP

Sep 29, 2016: Ablynx First-In-Class Wholly-Owned Anti-vWF Nanobody, Caplacizumab, May Have The Potential To Reduce Morbidity And Mortality Associated With Acquired TTP

May 26, 2016: Ablynx To Present A Post-Hoc Analysis Of The Phase II Titan Study

With Caplacizumab In Acquired Ttp Patients At The 21St Congress Of The European Hematology Association

Mar 24, 2016: U.S. FDA Grants Orphan Drug Designation to Anfibatide for Treatment of Thrombotic Thrombocytopenic Purpura

Feb 11, 2016: New England Journal Of Medicine Publishes Ablynx Phase II Titan Study Of Caplacizumab in Patients With Acquired TTP

Sep 29, 2015: Ablynx Initiates A Multinational Phase III Study With Caplacizumab In Patients With Acquired TTP

Jun 17, 2015: Ablynx Announces Presentations On Its Potential First-In-Class Treatment For Acquired TTP, Caplacizumab, At The 2015 Annual Meeting Of The ISTH

Feb 19, 2015: Omeros Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use

Dec 08, 2014: Additional Clinical Data From The Phase II Study With Ablynx'S Anti-Vwf Nanobody, Caplacizumab, Presented At The American Society Of Hematology Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Thrombotic Thrombocytopenic Purpura, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Thrombotic Thrombocytopenic Purpura - Pipeline by Ablynx NV, H2 2017

Thrombotic Thrombocytopenic Purpura - Pipeline by Biogen Inc, H2 2017

Thrombotic Thrombocytopenic Purpura - Pipeline by Kaketsuken, H2 2017

Thrombotic Thrombocytopenic Purpura - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017

Thrombotic Thrombocytopenic Purpura - Pipeline by Omeros Corp, H2 2017

Thrombotic Thrombocytopenic Purpura - Pipeline by Shire Plc, H2 2017

Thrombotic Thrombocytopenic Purpura - Dormant Projects, H2 2017

Thrombotic Thrombocytopenic Purpura - Discontinued Products, H2 2017



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Thrombotic Thrombocytopenic Purpura, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

### COMPANIES MENTIONED

Ablynx NV

Biogen Inc

Kaketsuken

Lee's Pharmaceutical Holdings Ltd

Omeros Corp

Shire Plc

## I would like to order

Product name: Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2017

Product link: <https://marketpublishers.com/r/T48665BFDCFEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T48665BFDCFEN.html>